Xiromed releases generic Nebcin
Nebcin and its generics had a market value of $16 million for the 12-month period ended April 2021, according to IQVIA.
Xiromed is launching tobramycin for injection, 1.2g.
The drug is a generic of Nebcin and is indicated to treat a variety of bacterial infections.
“Xiromed is focused on expanding our injectable offerings in order to create value for our institutional customers," Xiromed CEO Narasimhan Mani said. “We are excited for the launch of tobramycin vial for injection to advance our injectable strategy and further grow our injectable portfolio.”
Brand and generic versions of Nebcin had sales of $16 million for the 12 months ended April 2021, according to IQVIA.